YH 1226

Drug Profile

YH 1226

Latest Information Update: 19 Jun 2001

Price : $50

At a glance

  • Originator Yuhan
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 19 Jun 2001 No-Development-Reported for Bacterial infections in South Korea (Unknown route)
  • 12 Jan 1999 Preclinical development for Bacterial infections in South Korea (Unknown route)
  • 16 Jun 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top